The second half of may, the worst days of the year for those allergic to pollen in Spanish

Congress of the European Academy of Allergy and Clinical Immunology (EAACI 2012)

-A study measured from January to August the frequency and intensity of allergic symptoms with help from reminders via SMS

-allergy that sublingual immunotherapy received significantly reduced their Yessymptoms

Geneva, June 2012.- in the second half of may the Spanish allergic to grass pollen suffer more intensely the characteristic symptoms of allergic rhinitis. However, patients treated with sublingual immunotherapy in drops, with standardized extracts to 300 go, in pre-coestacional regime (four months before the station pollen during the entire season and interrupted at the end of this) improve significantly in all of your symptoms from one station to another. The authors of the SINTALEGRA study, whose findings were presented at the annual Congress of the European Academy of Allergy and Immunology clinic (EAACI), which took place in Geneva and tested it.

” In a sample of 177 Spanish patients with respiratory allergy (rhinoconjunctivitis and/or asthma) produced by pollen, mostly of grasses, the symptoms in a notebook that patients should be filled on a daily basis to assess the frequency and intensity of these were collected. This task was remembered through periodic SMS messages. There was the peak of symptoms during the second half of May. In the last week of may, 70% of patients had to take medication ”, explained the Albert doctor Roger, allergist Hospital Universitario Germans Trias i Pujol Badalona and one of the authors of this research.

The SINTALEGRA study was approved by the ethical Committee of research clinic (CEIC) of the Hospital Virgen of Macarena of Seville and 47 researchers spread throughout the Spanish geography have been involved in its realization. In addition, in the poster presented at EAACI have collaborated Hospital Universitario Germans Trias i Pujol of Hospital Materno Infantil perpetual relief of Badajoz, Badalona, Hospital Universitario Virgen Macarena of Seville, University Hospital of the Princess of Madrid and the Medical Department of Stallergenes Iberian.

SINTALEGRA is a multicentric and prospective observational study conducted between the months of January to August 2010. The researchers evaluated the frequency and intensity of six symptoms of rhinoconjunctivitis (nose itching, nasal congestion, runny nose, sneezing, eye itching and watery eyes), symptoms of asthma and the use of rescue medication. The intensity of the symptoms was measured from 0 to 5.

The seasonal type allergy is a global health problem; its prevalence has increased considerably in the last decades and everything seems to indicate that it will continue to grow. Clinical management of allergy include avoiding allergens, drug treatment, as tablets, antihistamines and nasal nebulizers with corticosteroids and immunotherapy (vaccination). (ITA1) allergen specific immunotherapy is recommended for patients who cannot be controlled despite symptomatic drug therapy. Few studies that describe the characteristics of symptomatic manifestations of patients allergic to grasses extensively over a long follow-up period, while the symptoms of allergy are regarded as very upset by patients and may impair their quality of life are known.

About Stallergenes

Stallergenes S.A. is a biopharmaceutical company international, a leader in the manufacture and innovation of allergen immunotherapy treatments. Stallergenes sells its products to prevent and control the allergic disease in 50 countries through more than 10 subsidiaries in Europe and 40 distribution agreements and collaboration throughout the world.

The factory of Stallergenes in Antony (France) is the largest center of production of allergen preparations especially for a patient (APEP) in the world, making more than 150 different allergens to treat more than 500,000 patients each year.

About 20% of the annual turnover of the pharmaceutical company it is intended for research and development.

Stallergenes Ibérica S.A. is the subsidiary of Stallergenes S.A. in Spain. Stallergenes Ibérica S.A. has one portfolio of products sufficient to treat 95% of patients with respiratory allergic diseases and has been since its implementation in Spanish territory marked 13 years, for a strong new products research work.

1. ARIA Guide 2008. Bousquet J, Khaltaev N Cruz AA Denburg J, Fokkens, WJ, Togias A., et to the. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA (2) LEN and AllerGen). Allergy 2008; 63 Suppl 86: 8-160.